Comparative Effectiveness, Safety, and Acceptability of Cannabis Use Disorder Treatments
| Journal | Addiction (Abingdon, England) |
| Study Type | Systematic Review |
| Population | Human participants |
Cannabis use disorder affects millions globally, yet evidence-based treatment options remain limited and poorly defined. This network meta-analysis provides the first comprehensive comparison of all available pharmacological and psychosocial interventions, offering critical guidance for clinicians managing CUD.
This network meta-analysis examined 57 studies comparing pharmacological and psychosocial interventions for cannabis use disorder in adults. The analysis included 6-36 studies per outcome measure, encompassing 260-3106 participants depending on the intervention category. Evidence for pharmacological interventions reducing cannabis use showed very high uncertainty, while psychosocial interventions demonstrated low-certainty evidence for benefit. The study assessed effectiveness through cannabis use levels, abstinence rates, adverse events, and treatment completion across different therapeutic approaches.
“This confirms what I see clinically—we lack robust pharmacological options for cannabis use disorder, unlike other substance use disorders. The uncertainty around medication effectiveness underscores why I focus primarily on behavioral interventions and motivational approaches when patients present with problematic cannabis use.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- Are there effective medications for treating cannabis use disorder?
- What psychosocial treatments work best for cannabis use disorder?
- How should treatment completion rates influence my choice of cannabis use disorder treatment?
- What does “low-certainty evidence” mean for clinical decision-making in cannabis use disorder treatment?
- How significant are the treatment effects found in this study?
- Read next
FAQ
Are there effective medications for treating cannabis use disorder?
According to this network meta-analysis of 57 studies, evidence for pharmacological interventions reducing cannabis use was very uncertain. Currently, there are no FDA-approved medications specifically for cannabis use disorder, and this research confirms the limited effectiveness of existing pharmacotherapies.
The study analyzed 6-16 psychosocial intervention studies involving up to 2,287 participants. While specific intervention rankings aren’t detailed in the provided summary, psychosocial approaches appear to show more promise than pharmacological treatments for reducing cannabis use and achieving abstinence.
How should treatment completion rates influence my choice of cannabis use disorder treatment?
Treatment completion was one of the key outcomes measured in this analysis, as it directly impacts treatment effectiveness. The network meta-analysis compared acceptability across different interventions, though specific completion rates aren’t provided in the summary, suggesting clinicians should consider patient preferences and intervention tolerability.
What does “low-certainty evidence” mean for clinical decision-making in cannabis use disorder treatment?
Low-certainty evidence means there is limited confidence in the treatment effects, and future research may significantly change these conclusions. Clinicians should interpret results cautiously and consider individual patient factors when making treatment recommendations for cannabis use disorder.
How significant are the treatment effects found in this study?
The study used clinically meaningful difference thresholds (mean difference ±0.05, odds ratios ≤0.8 or ≥1.25) to determine significance. This approach ensures that reported effects are not just statistically significant but also represent meaningful clinical improvements that would impact patient outcomes in real-world practice.
